Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sodium Cridanimod

Small molecule · developed by Xenetic Biosciences

Phase 2 Most advanced trial (none active)
XBIO Developer
1 Registered trials

What is Sodium Cridanimod?

Sodium Cridanimod is an agent studied in combination with progestin therapy in endometrial cancer, in patients who have failed progestin monotherapy or who are progesterone receptor negative.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Oncology
Developer
Xenetic Biosciences, Inc. (XBIO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03077698 Phase 2 Endometrial Cancer Terminated XBIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial Cancer

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XBIO page.

Follow XBIO, the company behind Sodium Cridanimod

See XBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XBIO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.